A randomized prospective trial of steroid withdrawal after liver transplantation

S. V. McDiarmid, D. A. Farmer, L. I. Goldstein, Paul Martin, J. Vargas, J. R. Tipton, F. Simmons, R. W. Busuttil

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The safety of steroid withdrawal in orthotopic liver transplant (OLT) recipients has been studied in a prospective trial with a comparison control group. Sixty-four recipients of ABO-compatible grafts (42 adults, 22 children) were randomized into a steroid withdrawal (SW) group and a control group. Inclusion criteria included survival > one year post-OLT and no rejection > six months after OLT. Exclusion criteria included previous graft loss secondary to rejection, > two episodes of documented rejection, patients transplanted for autoimmune hepatitis, and patients unable to receive azathioprine. Target HPLC cyclosporine levels in both groups were 100-200 ng/ml. Thirty-three patients entered the SW group and 31 the control group at a mean of 3.5 years after OLT; follow-ups were 592 and 527 days, respectively. Two patients in each group developed biopsy-proven rejection. In the SW group one patient rejected at three months, the other at nine months. Both rejection episodes resolved with only reinstitution of oral prednisone. Of the two patients who rejected in the control group (one at 7 months, one at 11 months) one required conversion to tacrolimus and the other intravenous steroids. There were no significant differences between the two groups for prednisone, azathioprine, cyclosporine doses, cyclosporine levels, liver function tests, and white blood cell counts at base line compared with 12 months. Fasting serum cholesterol in the SW group decreased from 194±44 mg/dl at baseline to 175±37 mg/dl at one year, whereas in the control group cholesterol rose from 180±48 mg/dl to 193±44 mg/dl. In pediatric patients no significant difference in age-adjusted height velocities over one year was seen between the two groups. We concluded that dual therapy with cyclosporine and azathioprine in stable long-term liver allograft recipients is not associated with an increase in rejection incidence. Prednisone withdrawal may be associated with an improvement in lipid profiles.

Original languageEnglish
Pages (from-to)1443-1450
Number of pages8
JournalTransplantation
Volume60
Issue number12
StatePublished - Dec 1 1995
Externally publishedYes

Fingerprint

Liver Transplantation
Steroids
Cyclosporine
Azathioprine
Control Groups
Prednisone
Liver
Transplants
Cholesterol
Autoimmune Hepatitis
Liver Function Tests
Graft Rejection
Tacrolimus
Leukocyte Count
Allografts
Fasting
High Pressure Liquid Chromatography
Rejection (Psychology)
Pediatrics
Lipids

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

McDiarmid, S. V., Farmer, D. A., Goldstein, L. I., Martin, P., Vargas, J., Tipton, J. R., ... Busuttil, R. W. (1995). A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation, 60(12), 1443-1450.

A randomized prospective trial of steroid withdrawal after liver transplantation. / McDiarmid, S. V.; Farmer, D. A.; Goldstein, L. I.; Martin, Paul; Vargas, J.; Tipton, J. R.; Simmons, F.; Busuttil, R. W.

In: Transplantation, Vol. 60, No. 12, 01.12.1995, p. 1443-1450.

Research output: Contribution to journalArticle

McDiarmid, SV, Farmer, DA, Goldstein, LI, Martin, P, Vargas, J, Tipton, JR, Simmons, F & Busuttil, RW 1995, 'A randomized prospective trial of steroid withdrawal after liver transplantation', Transplantation, vol. 60, no. 12, pp. 1443-1450.
McDiarmid SV, Farmer DA, Goldstein LI, Martin P, Vargas J, Tipton JR et al. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation. 1995 Dec 1;60(12):1443-1450.
McDiarmid, S. V. ; Farmer, D. A. ; Goldstein, L. I. ; Martin, Paul ; Vargas, J. ; Tipton, J. R. ; Simmons, F. ; Busuttil, R. W. / A randomized prospective trial of steroid withdrawal after liver transplantation. In: Transplantation. 1995 ; Vol. 60, No. 12. pp. 1443-1450.
@article{870102c8cdbc4757b20e0d4ce31a322c,
title = "A randomized prospective trial of steroid withdrawal after liver transplantation",
abstract = "The safety of steroid withdrawal in orthotopic liver transplant (OLT) recipients has been studied in a prospective trial with a comparison control group. Sixty-four recipients of ABO-compatible grafts (42 adults, 22 children) were randomized into a steroid withdrawal (SW) group and a control group. Inclusion criteria included survival > one year post-OLT and no rejection > six months after OLT. Exclusion criteria included previous graft loss secondary to rejection, > two episodes of documented rejection, patients transplanted for autoimmune hepatitis, and patients unable to receive azathioprine. Target HPLC cyclosporine levels in both groups were 100-200 ng/ml. Thirty-three patients entered the SW group and 31 the control group at a mean of 3.5 years after OLT; follow-ups were 592 and 527 days, respectively. Two patients in each group developed biopsy-proven rejection. In the SW group one patient rejected at three months, the other at nine months. Both rejection episodes resolved with only reinstitution of oral prednisone. Of the two patients who rejected in the control group (one at 7 months, one at 11 months) one required conversion to tacrolimus and the other intravenous steroids. There were no significant differences between the two groups for prednisone, azathioprine, cyclosporine doses, cyclosporine levels, liver function tests, and white blood cell counts at base line compared with 12 months. Fasting serum cholesterol in the SW group decreased from 194±44 mg/dl at baseline to 175±37 mg/dl at one year, whereas in the control group cholesterol rose from 180±48 mg/dl to 193±44 mg/dl. In pediatric patients no significant difference in age-adjusted height velocities over one year was seen between the two groups. We concluded that dual therapy with cyclosporine and azathioprine in stable long-term liver allograft recipients is not associated with an increase in rejection incidence. Prednisone withdrawal may be associated with an improvement in lipid profiles.",
author = "McDiarmid, {S. V.} and Farmer, {D. A.} and Goldstein, {L. I.} and Paul Martin and J. Vargas and Tipton, {J. R.} and F. Simmons and Busuttil, {R. W.}",
year = "1995",
month = "12",
day = "1",
language = "English",
volume = "60",
pages = "1443--1450",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - A randomized prospective trial of steroid withdrawal after liver transplantation

AU - McDiarmid, S. V.

AU - Farmer, D. A.

AU - Goldstein, L. I.

AU - Martin, Paul

AU - Vargas, J.

AU - Tipton, J. R.

AU - Simmons, F.

AU - Busuttil, R. W.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - The safety of steroid withdrawal in orthotopic liver transplant (OLT) recipients has been studied in a prospective trial with a comparison control group. Sixty-four recipients of ABO-compatible grafts (42 adults, 22 children) were randomized into a steroid withdrawal (SW) group and a control group. Inclusion criteria included survival > one year post-OLT and no rejection > six months after OLT. Exclusion criteria included previous graft loss secondary to rejection, > two episodes of documented rejection, patients transplanted for autoimmune hepatitis, and patients unable to receive azathioprine. Target HPLC cyclosporine levels in both groups were 100-200 ng/ml. Thirty-three patients entered the SW group and 31 the control group at a mean of 3.5 years after OLT; follow-ups were 592 and 527 days, respectively. Two patients in each group developed biopsy-proven rejection. In the SW group one patient rejected at three months, the other at nine months. Both rejection episodes resolved with only reinstitution of oral prednisone. Of the two patients who rejected in the control group (one at 7 months, one at 11 months) one required conversion to tacrolimus and the other intravenous steroids. There were no significant differences between the two groups for prednisone, azathioprine, cyclosporine doses, cyclosporine levels, liver function tests, and white blood cell counts at base line compared with 12 months. Fasting serum cholesterol in the SW group decreased from 194±44 mg/dl at baseline to 175±37 mg/dl at one year, whereas in the control group cholesterol rose from 180±48 mg/dl to 193±44 mg/dl. In pediatric patients no significant difference in age-adjusted height velocities over one year was seen between the two groups. We concluded that dual therapy with cyclosporine and azathioprine in stable long-term liver allograft recipients is not associated with an increase in rejection incidence. Prednisone withdrawal may be associated with an improvement in lipid profiles.

AB - The safety of steroid withdrawal in orthotopic liver transplant (OLT) recipients has been studied in a prospective trial with a comparison control group. Sixty-four recipients of ABO-compatible grafts (42 adults, 22 children) were randomized into a steroid withdrawal (SW) group and a control group. Inclusion criteria included survival > one year post-OLT and no rejection > six months after OLT. Exclusion criteria included previous graft loss secondary to rejection, > two episodes of documented rejection, patients transplanted for autoimmune hepatitis, and patients unable to receive azathioprine. Target HPLC cyclosporine levels in both groups were 100-200 ng/ml. Thirty-three patients entered the SW group and 31 the control group at a mean of 3.5 years after OLT; follow-ups were 592 and 527 days, respectively. Two patients in each group developed biopsy-proven rejection. In the SW group one patient rejected at three months, the other at nine months. Both rejection episodes resolved with only reinstitution of oral prednisone. Of the two patients who rejected in the control group (one at 7 months, one at 11 months) one required conversion to tacrolimus and the other intravenous steroids. There were no significant differences between the two groups for prednisone, azathioprine, cyclosporine doses, cyclosporine levels, liver function tests, and white blood cell counts at base line compared with 12 months. Fasting serum cholesterol in the SW group decreased from 194±44 mg/dl at baseline to 175±37 mg/dl at one year, whereas in the control group cholesterol rose from 180±48 mg/dl to 193±44 mg/dl. In pediatric patients no significant difference in age-adjusted height velocities over one year was seen between the two groups. We concluded that dual therapy with cyclosporine and azathioprine in stable long-term liver allograft recipients is not associated with an increase in rejection incidence. Prednisone withdrawal may be associated with an improvement in lipid profiles.

UR - http://www.scopus.com/inward/record.url?scp=0029598517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029598517&partnerID=8YFLogxK

M3 - Article

C2 - 8545872

AN - SCOPUS:0029598517

VL - 60

SP - 1443

EP - 1450

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -